| 商品名 | 申请号 | 产品号 | 申请类型 | 活性成分 | 剂型/给药途径 | 规格/剂量 | RLD | RS | 申请号原始批准/暂定批准日期 | 产品号批准日期 | 申请人 | 市场状态 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER | 019329 | 001 | NDA | SODIUM CHLORIDE | INJECTABLE;INJECTION | 234MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | Yes | No | -- | 1987/04/22 | ABRAXIS PHARM | Discontinued |
| SODIUM CHLORIDE 23.4% | 018897 | 003 | NDA | SODIUM CHLORIDE | SOLUTION;INTRAVENOUS | 400MEQ/100ML (4MEQ/ML) | Yes | Yes | 1984/07/20 | 2020/06/18 | HOSPIRA | Prescription |
| SODIUM CHLORIDE 23.4% | 212070 | 003 | ANDA | SODIUM CHLORIDE | SOLUTION;INTRAVENOUS | 400MEQ/100ML (4MEQ/ML) | No | No | 2021/04/28 | 2022/02/14 | FRESENIUS KABI USA | Prescription |
| SODIUM CHLORIDE 23.4% | 212248 | 001 | ANDA | SODIUM CHLORIDE | INJECTABLE;INJECTION | 234MG/ML | No | No | 2021/04/28 | 2021/04/28 | FRESENIUS KABI USA | Prescription |
| SODIUM CHLORIDE 23.4% | 217796 | 001 | ANDA | SODIUM CHLORIDE | INJECTABLE;INJECTION | 234MG/ML | No | No | 2023/07/11 | 2023/07/11 | FRESENIUS KABI USA | Prescription |